Clinical evaluation of the SSSLTVPWY peptide labeled with 99m TC

Not Applicable

• Conditions: breast cancer.; Malignant neoplasm of breast of unspecified site, female; C50.91

• Registration Number: IRCT20180310039019N1
• Lead Sponsor: Mazandaran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 25

Inclusion Criteria

Female
Primary breast cancer
Size greater than 2cm
Without any history of biopsy

Exclusion Criteria

Renal failure
Liver dysfunction
Pregnancy
Lactation

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Radiotracer uptake by breast cancer. Timepoint: Imaging of the breast at 1,2,3 and 4 hours after the administration of the Radiopeptide. Method of measurement: With imaging.

Secondary Outcome Measures

Name	Time	Method
Distribution of radiopeptide in other tissues. Timepoint: Imaging at 1,2,3 and 4 hours after the administration of the radiopeptide. Method of measurement: With imaging.